logowsbdaily | Mon, 26 Sep 2022 03:58:39 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Helius Medical Technologies, Inc.
(HSDT)

Helius Medical Technologies, Inc.
642 Newtown Yardley Road
Suite 100
Newtown, PA 18940
United States
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunctio... Read More

Summary & Charts

Price$ 0.35-0.01 (-2.78%)
Day's Range$ 0.33 - 0.36 
Previous Close$ 0.36
Market Cap$ 10.15M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqCM
IndustryMedical Devices
SectorHealthcare
Volume999.48K
Avg. Volume (20 day)2.37M
Rel. Volume (20 day)0.42
Rel. Volume (3 month)0.23
RatingBNeutral
DCFN/AStrong Buy
Debt/Equity45.40 %Neutral
ROE-242.72 %Strong Sell
ROA-268.54 %Strong Sell
P/E-0.08 %Neutral
P/B0.31 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Sep 23, 2022$ 0.35$ 0.36$ 0.33$ 0.35-0.01999,4780.420.23
Sep 22, 2022$ 0.42$ 0.42$ 0.35$ 0.36-0.083,260,9391.210.771
Sep 21, 2022$ 0.46$ 0.47$ 0.43$ 0.44-0.041,283,1340.430.31
Sep 20, 2022$ 0.50$ 0.50$ 0.45$ 0.47-0.021,383,5470.240.34
Sep 19, 2022$ 0.50$ 0.51$ 0.47$ 0.49-0.031,264,2000.210.31
Sep 16, 2022$ 0.52$ 0.53$ 0.49$ 0.52-0.011,369,4500.220.34
Sep 15, 2022$ 0.52$ 0.54$ 0.51$ 0.53+0.011,260,2250.200.32
Sep 14, 2022$ 0.53$ 0.54$ 0.50$ 0.52-0.021,604,6060.250.42
Sep 13, 2022$ 0.55$ 0.55$ 0.52$ 0.54-0.021,353,4180.200.301
Sep 12, 2022$ 0.56$ 0.57$ 0.53$ 0.56-0.011,021,3220.150.23
Sep 09, 2022$ 0.55$ 0.58$ 0.51$ 0.57+0.021,675,7150.230.39
Sep 08, 2022$ 0.55$ 0.59$ 0.53$ 0.55-0.002,266,6300.310.53
Sep 07, 2022$ 0.54$ 0.56$ 0.51$ 0.55-0.012,183,4030.280.511
Sep 06, 2022$ 0.53$ 0.56$ 0.52$ 0.56+0.042,916,3320.360.671
Sep 02, 2022$ 0.51$ 0.53$ 0.51$ 0.52-0.011,244,6360.150.29
Sep 01, 2022$ 0.53$ 0.54$ 0.47$ 0.53-0.023,418,8140.360.78
Aug 31, 2022$ 0.54$ 0.56$ 0.53$ 0.55-0.012,362,4240.240.542
Aug 30, 2022$ 0.56$ 0.60$ 0.53$ 0.56+0.048,128,1740.701.831
Aug 29, 2022$ 0.55$ 0.55$ 0.52$ 0.52-0.012,141,9810.190.49
Aug 26, 2022$ 0.57$ 0.59$ 0.52$ 0.54-0.046,299,8980.561.43

News

The latest news about Helius Medical Technologies, Inc. (HSDT).

PennyStocks | 2022-09-08 10:40:58
Penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $0.99 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire | 2022-09-06 06:30:00
NEWTOWN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at two upcoming healthcare conferences as follows:
Seeking Alpha | 2022-08-23 08:03:59
A curious $14.5m microcap that $100m in value has transacted through in just 15 trading sessions. A recent equity raise increased cash position by $16.4m in August. The company is currently net-net trading below net current asset value. P/B is 0.69x.
Zacks Investment Research | 2022-08-18 13:33:21
Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Seeking Alpha | 2022-08-15 19:08:03
Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Lisa Wilson - Investor Relations Dane Andreeff - President & Chief Executive Officer Jeff Mathiesen - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Operator Good day and thank you for standing by. Welcome to the Helius Medical Technologies' Q2 2022 Earnings Conference Call.
GlobeNewsWire | 2022-08-10 07:05:00
NEWTOWN, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company will release its second quarter 2022 financial results on Monday, August 15, 2022, after the market closes.
PennyStocks | 2022-07-12 15:32:53
Check these penny stocks out for your watchlist right now The post Big Gaining Penny Stocks to Buy? 3 to Watch Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-11-08AMC-0.21----170K----
2022-08-15AMC-1.12-0.9713.4%------
2022-05-12AMC-1.13-1.151.76%187K190K1.8%
2022-03-14AMC-1.16-1.3112.93%160K258K61.25%
2021-11-10AMC-1.75-2.0114.85%93K109K17.45%
2021-08-12AMC-1.53-2.5868.62%55K71K28.79%
2021-05-17AMC------------
2020-11-12AMC-0.09----------

Top Discussions

These are the top discussions over the last 24-hours that mention the HSDT stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Thu, 9 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.